Recce Pharmaceuticals (ASX:RCE) entered into a cooperative research and development agreement with the United States Army Institute of Surgical Research to evaluate its RECCE 327 gel therapy candidate in their validated Walker-Mason rat model of burn wound infection, according to a Monday Australian bourse filing.
The study will evaluate whether the gel can significantly reduce bacterial burden in infected burn wounds against methicillin-resistant bacterial pathogens, Staphylococcus aureus and Pseudomonas aeruginosa.